Daily Alpha · Reddit
· Premarket Alpha · by Buzzberg Research
Reddit’s strongest material paired a two-sided AI and memory debate with several concrete event, balance-sheet and market-structure setups.
Themes on this desk
AI pacing versus compute
Posts disagree on whether safety pacing cuts capex, adds alignment compute or leaves bipartisan infrastructure spending intact; all three claims remain user-authored theses.
Memory cycle split
SNDK was shorted as the highest-beta cycle peak while MU was framed as deeply undervalued at five times forward earnings, setting a direct earnings test.
Highest engagement
by score · day changeATAI LEAPS holders wiped out by OCC expiration acceleration after Lilly acquisition
A holder of 102 ATAI call options (mostly $8 and $10 strikes, expiring 2027 and Jan 2028, ~$1k cost) reports that after Lilly agreed to buy ATAI for $6.75/share plus a CVR worth up to $2.50/share, OCC accelerated all contracts to 9/18/26 and excluded the CVR, cutting ~495 days of time value to 5 days and rendering the $8 and $10 calls essentially worthless.
Now OCC has accelerated ALL my options to 9/18/26 and excluded the CVR from the option contracts.
It is a concrete, structural risk disclosure for long-dated options: cash acquisitions can collapse LEAPS time value and strip contingent consideration (CVRs) from the contract, a hazard that is underappreciated by retail option buyers.
Watch Whether OCC provides any adjustment or recourse for the excluded CVR, and whether similar acceleration clauses trigger in other pending cash takeouts with CVR structures.
Source →Constellation Energy long thesis built on contracted data-center demand and 20%+ EPS growth
A holder discloses buying 100 CEG shares at $288 (about 10% of the account, targeting up to 30%), citing data-center power demand showing up in signed contracts, guidance for 20%+ base EPS growth through 2029, a stock down ~31% from highs, and a $418k August director purchase described as the only insider buy in two years.
20%+ base EPS growth through 2029. Stock is down around 31% from the highs.
This is a concrete, checkable bull case linking AI power demand to contracted revenue rather than sentiment, and the disclosed insider purchase is a specific corroborating datapoint.
Watch Whether CEG guidance for 20%+ EPS growth through 2029 is reaffirmed and whether additional insider buying follows the August purchase.
Source →Roivant bull case shifts from clinical survival to commercial execution
A bullish write-up argues FDA approval of brepocitinib/LISRAYA delivered Roivant's first commercial product and the Phase-2 PHocus readout for mosliciguat sparked a 17-20% one-day surge, transforming the risk profile toward commercial execution and insulating it from higher-for-longer rates given cash runway.
delivered Roivant’s first commercial product, while the **Phase‑2 PHocus readout for mosliciguat** sparked a **17‑20% one‑day price surge**.
The thesis explicitly reframes ROIV from binary clinical risk to launch-execution risk, which changes what data points matter for holders.
Watch LISRAYA commercialization metrics and the next IMVT-1402 readouts; failure to convert approval into revenue would invalidate the reframing.
Source →SPCX bear case: capex dwarfs revenue, FCF may never justify valuation
Author argues SpaceX (SPCX) Q2 produced roughly $7.8B revenue against ~$18.4B capex, and that capital intensity across Starlink, Starship, and AI/X/Grok means sustainable free cash flow may never approach what shareholders pay today; cites Morningstar fair value of $62.
flow?** Q2 reportedly produced roughly $7.8B of revenue against \~$18.4B of capex.
A detailed capital-intensity short thesis on the most valuable private space/AI conglomerate; relevant to pre-IPO token pricing and any eventual public-market valuation anchor.
Watch Segment capex and satellite replacement cycles in future disclosures; narrowing capex-to-revenue gap would weaken the thesis.
Source →SPX negative skew setup with defined downside accelerators
Author argues SPX has a negatively skewed week with 50pts upside versus 150pts downside, 7650 as point of control, 7500 lower bound, and charm/delta decay flows driving a slide if price stays below 7650 into Wednesday's FOMC.
skew. 7700 is the upside 7650 is the point of control and 7500 is the lower bound.
Provides concrete, falsifiable index levels and a flow-based mechanism for the week's direction, useful for options positioning around FOMC and OPEX.
Watch Whether SPX holds above 7650 into Wednesday; a break below 7625/7575 would confirm the accelerator path toward 7500.
Source →Most argued
by comments per upvoteAI-led deflation: clients demanding discounts on renewal pricing
The post argues the real issue is pricing, not layoffs: clients believe AI makes delivery cheaper and want that discount, with Infosys calling it 'AI led deflation' that hits small contracts too, not just large renewals.
so revenue barely moves. * Infosys called it "AI led deflation" and said it hits small contracts too not just
Pricing deflation is harder to reverse than cyclical demand weakness, so it compresses margins structurally rather than temporarily.
Watch Watch reported pricing and margin commentary at renewal cycles; if Infosys and peers report stabilizing or improving pricing, the deflation thesis weakens.
Source →Lovesac buybacks and insider buying cited as catalysts
The author says the company has retired 3% of the float via buybacks since the original post, insiders bought another 1.5% in what are described as uncharacteristic purchases, and roughly $50M remains available under the buyback plan.
Insiders have bought another 1.5% in uncharacteristic buys. There is still roughly $50M in the buyback plan available.
Aggressive buybacks and insider purchases at a $200M market cap can signal management's view of intrinsic value and tighten the float, amplifying any re-rating.
Watch Subsequent 13D/13G and Form 4 filings confirming insider purchases, and quarterly share-count reduction versus the stated $50M remaining authorization.
Source →Sprouts framed as value buy after >50% drawdown at under 14x P/E
A value investor argues SFM is attractive after falling more than 50% from its 52-week high to under 14x P/E, with the business still profitable, generating strong cash flow, carrying essentially no conventional long-term debt, reducing share count, and targeting roughly 10% annual unit growth with private label improving margins.
SFM looks interesting to me as a potential value buy since it followed the same suit, with SFM dropping >50%
The bull case rests on store expansion driving EPS growth without multiple expansion, so the debate is whether slightly negative same-store sales are a structural slowdown or a justified repricing of an otherwise intact growth story.
Watch Watch same-store sales comps and unit growth in the next report; a return to positive comps would confirm the value thesis, while continued negative comps would validate the market's repricing.
Source →Rumble short squeeze setup on Anthropic data-center deal and tight float
Author claims RUM landed a major Anthropic data-center deal and that heavy short interest with a tight float could fuel a squeeze.
RUM STOCK JUST GOT HUGE ANTHROPIC DEAL FOR ITS DATA CENTER CRAZY SHORT INTEREST WITH TIGHT FLOAT
A named hyperscaler-adjacent customer deal plus a crowded short base is the classic ingredients for a violent squeeze, making RUM a high-risk/high-reward event-driven name; it also signals AI data-center demand broadening beyond the usual suspects.
Watch Confirmation of the Anthropic deal terms and short interest/borrow data; failure to confirm the deal or rising float would invalidate the squeeze thesis.
Source →